The use of diagnostic biomarkers, such as the serum prostate-specific antigen (PSA), which is commonly used for PCa screening, prostatic acid phosphate (PAP), and prostate-specific membrane antigen (PSMA), as target antigens in immunotherapy has been investigated [32,35]. This evidence concerns the gene FOLH1 and posterior cortical atrophy.